New leukemia combo shows promise in early trial

NCT ID NCT07512700

Recruiting now Disease control Sponsor: Chinese PLA General Hospital Source: ClinicalTrials.gov ↗

First seen Apr 06, 2026 · Last updated May 14, 2026 · Updated 3 times

Summary

This study compares a new treatment (venetoclax plus CACAG chemo) to the standard 3+7 chemo for people with acute monocytic leukemia. About 204 patients aged 14-60 will take part. The goal is to see if the new combo leads to more complete remissions after one cycle of treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MONOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Air Force Medical Center, PLA
RECRUITING

Beijing, China

Contact Phone: •••-•••-•••• Email: •••••@•••••
Chinese PLA General Hospital
RECRUITING

Beijing, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••
PLA Strategic Support Force's Characteristic Medical Center
RECRUITING

Beijing, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

ACUTE MONOCYTIC LEUKEMIA